{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer+in+Normal+and+Malignant+Tumors&page=10",
    "query": {
      "condition": "Lung Cancer in Normal and Malignant Tumors",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 845,
    "total_pages": 85,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer+in+Normal+and+Malignant+Tumors&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer+in+Normal+and+Malignant+Tumors&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T23:10:29.479Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03093116",
      "title": "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Solid Tumors",
        "Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Oral repotrectinib (TPX-0005)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Turning Point Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2017-03-07",
      "completion_date": "2028-02-29",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-10-13T23:10:29.479Z",
      "location_count": 49,
      "location_summary": "Duarte, California • Glendale, California • La Jolla, California + 36 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03093116"
    },
    {
      "nct_id": "NCT00710697",
      "title": "Cardiac Safety Assessment Study of Picoplatin in Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Picoplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Poniard Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2008-06",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2009-09-24",
      "last_synced_at": "2026-10-13T23:10:29.479Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00710697"
    },
    {
      "nct_id": "NCT02122861",
      "title": "Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma - Currently Enrolling",
        "Non-small Cell Lung Cancer - Enrollment Completed",
        "Sarcoma - Enrollment Completed"
      ],
      "interventions": [
        {
          "name": "ID-LV305",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 47,
      "start_date": "2014-05-30",
      "completion_date": "2018-12-15",
      "has_results": false,
      "last_update_posted_date": "2019-03-06",
      "last_synced_at": "2026-10-13T23:10:29.479Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • New Haven, Connecticut • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02122861"
    },
    {
      "nct_id": "NCT04068896",
      "title": "Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Metastatic Castration-resistant Prostate Cancer",
        "Bladder Cancer",
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Ovarian Cancer",
        "Head Neck Squamous Cell Carcinoma",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "NGM120 30mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 100mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 30mg with Gemcitabine and Abraxane",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 100mg with Gemcitabine and Abraxane",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 100mg Q3W",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2019-10-16",
      "completion_date": "2024-01-08",
      "has_results": true,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-10-13T23:10:29.479Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04068896"
    },
    {
      "nct_id": "NCT02988960",
      "title": "A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors Cancer"
      ],
      "interventions": [
        {
          "name": "ABBV-927",
          "type": "DRUG"
        },
        {
          "name": "ABBV-181",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 163,
      "start_date": "2017-02-22",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-13T23:10:29.479Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02988960"
    },
    {
      "nct_id": "NCT04423029",
      "title": "A Study of DF6002 Alone and in Combination With Nivolumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "DF6002",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dragonfly Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2020-07-13",
      "completion_date": "2025-11-26",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-10-13T23:10:29.479Z",
      "location_count": 21,
      "location_summary": "Orange, California • Denver, Colorado • New Haven, Connecticut + 17 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04423029"
    },
    {
      "nct_id": "NCT05194072",
      "title": "A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Peritoneal Neoplasms",
        "Fallopian Tube Neoplasms",
        "Triple Negative Breast Neoplasms",
        "HER2 Negative Breast Neoplasms",
        "Hormone Receptor Positive Breast Neoplasms",
        "Endometrial Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Cholangiocarcinoma",
        "Gallbladder Carcinoma",
        "Adenoid Cystic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Felmetatug Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2022-01-12",
      "completion_date": "2025-05-14",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-13T23:10:29.479Z",
      "location_count": 22,
      "location_summary": "Aurora, Colorado • Denver, Colorado • Celebration, Florida + 9 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05194072"
    },
    {
      "nct_id": "NCT02029729",
      "title": "RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic or Incurable Non-small Cell Lung Cancer",
        "Relapsed, Refractory Melanoma"
      ],
      "interventions": [
        {
          "name": "omaveloxolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 11,
      "start_date": "2013-12-31",
      "completion_date": "2015-10-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-10-13T23:10:29.479Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02029729"
    },
    {
      "nct_id": "NCT05076760",
      "title": "MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Advanced Cancer",
        "Metastatic Cancer",
        "Non Small Cell Lung Cancer",
        "Cutaneous Squamous Cell Carcinoma",
        "Merkel Cell Carcinoma",
        "Melanoma",
        "Pancreatic Cancer",
        "Triple Negative Breast Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "MEM-288 Intratumoral Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Memgen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2022-04-21",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-10-13T23:10:29.479Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Durham, North Carolina",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05076760"
    },
    {
      "nct_id": "NCT06034860",
      "title": "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Hepatocellular Carcinoma",
        "Melanoma",
        "Renal Cell Carcinoma",
        "Microsatellite Instability High",
        "Mismatch Repair Deficiency",
        "Mesothelioma",
        "Esophageal Squamous Cell Carcinoma",
        "Squamous Cell Carcinoma of Head and Neck",
        "Urothelial Carcinoma",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "MT-8421",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Molecular Templates, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2023-11-01",
      "completion_date": "2024-10-31",
      "has_results": false,
      "last_update_posted_date": "2024-11-01",
      "last_synced_at": "2026-10-13T23:10:29.479Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Lafayette, Indiana • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06034860"
    }
  ]
}